Philadelphia Trust Company’s Neurocrine Biosciences NBIX Stock Holding History

Philadelphia Trust Company’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.7M	Sell	28,098 -662	-2%	-$87.8K	0.26%	64
2025 Q4	$4.08M	Sell	28,760 -900	-3%	-$130K	0.28%	62
2025 Q3	$4.16M	Sell	29,660 -5,000	-14%	-$677K	0.29%	61
2025 Q2	$4.36M	Hold	34,660	–	–	0.33%	55
2025 Q1	$3.83M	Sell	34,660 -1,750	-5%	-$222K	0.33%	60
2024 Q4	$4.97M	Buy	36,410 +29,685	+441%	+$3.67M	0.36%	58
2024 Q3	$775K	Buy	+6,725	New	+$922K	0.06%	133

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Philadelphia Trust Company's NBIX Position: Q1 2026 in Review

Philadelphia Trust Company reduced its Neurocrine Biosciences (NBIX) stake by 2.3% in Q1 2026, selling an estimated $87.8K and leaving 28,098 shares worth $3.7M. The position accounts for 0.26% of the portfolio, ranked #64.

Philadelphia Trust Company first reported a position in NBIX in Q3 2024 and has held it in 7 quarters since. The position peaked at $4.97M in Q4 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Philadelphia Trust Company held 28,098 shares of Neurocrine Biosciences worth $3.7M as of Q1 2026.
Philadelphia Trust Company sold 662 Neurocrine Biosciences shares in Q1 2026, an estimated $87.8K.
Neurocrine Biosciences made up 0.26% of Philadelphia Trust Company's portfolio in Q1 2026, its #64 holding.
Philadelphia Trust Company first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 7 quarters since.
Philadelphia Trust Company's Neurocrine Biosciences position peaked at $4.97M in Q4 2024.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Philadelphia Trust Company's 13F filing for Q1 2026, filed 13 May 2026.